November 19, 2016

ASN 2016 Rabbit-ATG or Basiliximab Induction for Rapid Steroid Withdrawal after Renal Transplantation: An Open-Label, Multicentre, Randomized Controlled Trial

High Impact Clinical Trial Session at the 2016 ASN

Christian Hugo, Michael Sean Wiesener, Mirian Opgenoorth, Oliver Thomusch. Dresden, Germany

In low-tacrolimus treated, immunologically low-risk renal transplant recipients, rapid steroid withdrawal is safe with no impact on survival or biopsy-proven acute rejection.  Post-transplantation diabetes incidence is reduced from 39.2% to 23.9%(Basiliximab) or 22.7% (rATG) in rapid steroid withdrawal.

Related Articles:

Clinical Trial Results, Conference Alert